Literature DB >> 22069029

Hit clustering can improve virtual fragment screening: CDK2 and PARP1 case studies.

Alexey A Zeifman1, Victor S Stroylov, Fedor N Novikov, Oleg V Stroganov, Alexandra L Zakharenko, Svetlana N Khodyreva, Olga I Lavrik, Ghermes G Chilov.   

Abstract

Virtual fragment screening could be a promising alternative to existing experimental screening techniques. However, reliable methods of in silico fragment screening are yet to be established and validated. In order to develop such an approach we first checked how successful the existing molecular docking methods can be in predicting fragment binding affinities and poses. Using our Lead Finder docking software the RMSD of the binding energy prediction was observed to be 1.35 kcal/mol(-1) on a set of 26 experimentally characterized fragment inhibitors, and the RMSD of the predicted binding pose from the experimental one was <1.5 Å. Then, we explored docking of 68 fragments obtained from 39 drug molecules for which co-crystal structures were available from the PDB. It appeared that fragments that participate in oriented non-covalent interactions, such as hydrogen bonds and metal coordination, could be correctly docked in 70-80% of cases suggesting the potential success of rediscovering of corresponding drugs by in silico fragment approach. Based on these findings we've developed a virtual fragment screening technique which involved structural filtration of protein-ligand complexes for specific interactions and subsequent clustering in order to minimize the number of preferable starting fragment candidates. Application of this method led to 2 millimolar-scale fragment PARP1 inhibitors with a new scaffold.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22069029     DOI: 10.1007/s00894-011-1280-4

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  54 in total

1.  Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor.

Authors:  James E Thompson; Rose M Cubbon; Richard T Cummings; Linda S Wicker; Robert Frankshun; Barry R Cunningham; Patricia M Cameron; Peter T Meinke; Nigel Liverton; Youmin Weng; Julie A DeMartino
Journal:  Bioorg Med Chem Lett       Date:  2002-04-22       Impact factor: 2.823

2.  A 'rule of three' for fragment-based lead discovery?

Authors:  Miles Congreve; Robin Carr; Chris Murray; Harren Jhoti
Journal:  Drug Discov Today       Date:  2003-10-01       Impact factor: 7.851

Review 3.  Target-based drug discovery: is something wrong?

Authors:  Frank Sams-Dodd
Journal:  Drug Discov Today       Date:  2005-01-15       Impact factor: 7.851

4.  Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration.

Authors:  John J Caldwell; Thomas G Davies; Alastair Donald; Tatiana McHardy; Martin G Rowlands; G Wynne Aherne; Lisa K Hunter; Kevin Taylor; Ruth Ruddle; Florence I Raynaud; Marcel Verdonk; Paul Workman; Michelle D Garrett; Ian Collins
Journal:  J Med Chem       Date:  2008-03-18       Impact factor: 7.446

5.  Fragment-based drug discovery.

Authors:  Wendy A Warr
Journal:  J Comput Aided Mol Des       Date:  2009-06-24       Impact factor: 3.686

6.  Identification of novel inhibitors of urokinase via NMR-based screening.

Authors:  P J Hajduk; S Boyd; D Nettesheim; V Nienaber; J Severin; R Smith; D Davidson; T Rockway; S W Fesik
Journal:  J Med Chem       Date:  2000-10-19       Impact factor: 7.446

7.  Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein.

Authors:  M Ikuta; K Kamata; K Fukasawa; T Honma; T Machida; H Hirai; I Suzuki-Takahashi; T Hayama; S Nishimura
Journal:  J Biol Chem       Date:  2001-05-02       Impact factor: 5.157

8.  Application of fragment screening by X-ray crystallography to beta-secretase.

Authors:  Christopher W Murray; Owen Callaghan; Gianni Chessari; Anne Cleasby; Miles Congreve; Martyn Frederickson; Michael J Hartshorn; Rachel McMenamin; Sahil Patel; Nicola Wallis
Journal:  J Med Chem       Date:  2007-02-22       Impact factor: 7.446

9.  Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator.

Authors:  Martyn Frederickson; Owen Callaghan; Gianni Chessari; Miles Congreve; Suzanna R Cowan; Julia E Matthews; Rachel McMenamin; Donna-Michelle Smith; Mladen Vinković; Nicola G Wallis
Journal:  J Med Chem       Date:  2007-12-29       Impact factor: 7.446

10.  Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.

Authors:  Gudrun Lange; Dominique Lesuisse; Pierre Deprez; Bernard Schoot; Petra Loenze; Didier Bénard; Jean-Pierre Marquette; Pierre Broto; Edoardo Sarubbi; Eliane Mandine
Journal:  J Med Chem       Date:  2003-11-20       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.